IN THE PRESS: 7 Ways Investors Can Gain Clarity While Conducting Technical Due Diligence  Read More

NEW FUNDING: Why Volition Capital Invested in Doing Things Media (DTM)  Read More

VOLITION NEWS: Claude de Jocas in Built In Boston: Local VC Firm Fuels Startups Targeting Underserved Groups Despite Funding Slowdown  Read More

NEW FUNDING: Why We Invested in US Mobile  Read More

SCALING SUCCESS PODCAST: Sean Cantwell interviews Paul Melchiorre for Scaling Success  Read More

Categories:
Categories:
Categories:
Portfolio News

CNBC: TraceLink CEO Shabbir Dahod on securing the Covid-19 vaccine supply chain

Volition Press
Volition

Shabbir Dahod, CEO of our portfolio company, TraceLink, recently joined CNBC’s Worldwide Exchange to discuss the process of securing the supply chain for the Covid-19 vaccine rollout.

TraceLink has been involved in securing the pharmaceutical supply chain for over a decade, and Shabbir has extensive knowledge of the challenges that will arise as various COVID-19 vaccines begin to disseminate.

In fact, TraceLink has built the largest track and trace network in the world for pharmaceutical drugs, with over 280,000 entities, which gives it tremendous insight into this process.

Watch the entire interview on CNBC here!

Similar Articles